Meeting Agenda

Meeting Co-Chairs: Larry Kerr and John Ryan

Wednesday, March 7

weullesuay, ivial cit 7			
7:30-8:30 a.m.	Registration		
	Opening Session	Aud. B3	
8:45 a.m.	Welcome from the Co-Chairs		
	Larry Kerr, U.S. TATFAR Co-Chair		
	Director, Office of Pandemics and Emerging Threats		
	U.S. Department of Health and Human Services (HHS)		
	John F. Ryan, EU TATFAR Co-Chair		
	Director for Public Health, Country Knowledge and Crisis Management		
	European Commission		
9:00 a.m.	Keynote Speakers		
	Xavier Prats-Monné		
	Director General for Health and Food Safety,		
	European Commission		
	Anne Schuchat		
	Acting Director		
	U.S. Centers for Disease Control and Prevention (CDC)		
9:30 a.m.	Break		

9:30 a.m.	Break	
9:45 a.m.	Engaging Partners on AMR Moderated panel discussion on strategies to motivate action on AMR	Aud. B3
	Co-Moderator: Michael Craig Senior Adviser, Antimicrobial Resistance Coordination and Strategy Unit, CDC	
	Co-Moderator: Kathy Talkington Director, Antibiotic Resistance Project The Pew Charitable Trusts (Pew)	

Panel: Ed Whiting (Wellcome Trust); Paul Aurwaerter (Infectious Disease Society of America (IDSA); Torstein Lindstad (Ministry of Health and Care Services, Norway)

11:15 a.m. Implementation of AMR Strategy at the Local Level

Aud. B3

Panel of speakers from EU, Norway, U.S., and Canada discuss strategies to support local level action on AMR and government collaboration to implement National Action Plans

Moderator: John F. Ryan

Director for Public Health, Country Knowledge and Crisis Management, European Commission

Panel: Jean Patel (CDC); Marion Kainer (Tennessee Department of Health); Howard Njoo (Public Health Agency of Canada); Andrew Morris (University Health Network, Toronto); Norway: Morten Lindbæk (University of Oslo, Institute of Health and Society)

12:30-1:30 p.m. Lunch Break

1:30-3:00 p.m. Stewardship in Human Medicine

Aud. B3

Panel of experts to discuss how country and partner policies drive antibiotic stewardship implementation. TATFAR Key Area 1: Appropriate therapeutic use of antimicrobials.

Moderator: Lauri Hicks

Director, Office of Antibiotic Stewardship, CDC

Panel: Diamantis Plachouras (ECDC) Yoshiko Nakamachi (University Health Network, Toronto); José Miguel Cisneros (University Hospital Virgen del Rocío, Seville)

3:00-3:15 p.m. Break

3:15-3:30 p.m. FAO's One Health Approach to AMR

Aud. B3

Henk Jan Ormel

Senior Veterinary Policy Advisor

Animal Health Service

Food and Agriculture Organization of the United Nations (FAO)



3:30-5 p.m. Measuring Antimicrobial Consumption in Animals

Aud. B3

Panel of experts to discuss the status of the collection of data on antimicrobial consumption by animal species, including the status of the calculation of the animal biomass, and possible standards to report such data. TATFAR Key Area 1: Appropriate therapeutic use of antimicrobials.

Moderator: Jordi Torren Edo

Head of Service of Veterinary Risk and Surveillance, European Medicines Agency

(EMA)

Panel: Kari Grave (Norwegian Veterinary Institute (NVI)); Kelly Roy (U.S. Food and Drug Administration (FDA)); Susan Bright (FDA); Carolee Carson (PHAC); Margot

Raicek (World Organization for Animal Health (OIE))

Thursday, March 8

8:30 a.m.	Welcome	Aud. B1/B2
8:45-10:45 a.m.	Strategies for Improving the Pipeline of New Antimicrobial Drugs (TATFAR Key Area 3)	Aud. B1/B2
8:45 a.m.	Introduction: Ed Whiting Director of Policy & Chief of Staff Wellcome Trust	
8:50 a.m.	The Role of TATFAR and the AMR Research & Development (R&D) Hub	
9 a.m.	TATFAR-mission, goals, accomplishments related to Key Area 3: Arjon van Hengel, (EU); Dennis Dixon (NIH)	
9:20 a.m.	An overview of the Global AMR R&D Hub: Marit Ackermann (German Federal Ministry of Education and Research)	
	Panel discussion regarding future synergies with other initiatives: Joe Larsen (BARDA); Kevin Outterson (CARB-X); Manica Balasegaram (GARDP); Laura Marin (JPIAMR); Kathy Talkington (PEW); Marit Ackermann (German Federal Ministry of Education and Research)	

TATFAR

2018 Meeting of the Transatlantic Taskforce on Antimicrobial Resistance

Strengthening Partnerships in the Fight against AR! Atlanta, GA | March 7-9, 2018

9:50 a.m. Pull Incentives for Antibacterial Innovation and Potential Financing Sources
 10 a.m. Assessing the societal value of antibiotics through augmented health technology

assessments: Rory Constable (UK Department of Health)

Market Entry Rewards – Financing and implementation: Christine Ardal (DRIVE-

AB and EU Joint Action)

10:15 a.m. Panel discussion regarding the initiation of pilot(s) to test the feasibility and

impact of pull incentive(s): Torstein Lindstad (Norwegian Ministry of Health and Care Services); Amanda Jezek (IDSA); Randall Mariger (U.S. Department of Treasury); Regine Aalders (Netherlands Embassy); Rory Constable (UK)

10:50-11 a.m. Break

11 a.m.-1 p.m. Detect and Respond: Translating Data into Action

Aud. B1/B2

How to use surveillance data (Point Prevalence Survey, i.e.PPS, data) for prevention. TATFAR Key Area 2: Prevention of drug-resistant infections.

Moderator: Jean Patel

Health Scientist, Antimicrobial Resistance Coordination and Strategy Unit

CDC

Presentation 1: Overview of PPS survey results

Shelley Magill (CDC); Diamantis Plachouras (ECDC); Chris Archibald (PHAC),

Øyunn Holen (Norwegian Institute of Public Health (NIPH))

Presentation 2: Examples of data for action

Nicola Thompson (CDC); Diamantis Plachouras (ECDC); Øyunn Holen (NIPH)

1-1:45 p.m. Lunch

Working Group Meetings: Round of breakouts to actively work on TATFAR Actions and develop work plan for second half of implementation period.

1:45-3:15 p.m. Session 1

Action 1.1 - Guidance for assessing appropriate antibiotic use (CDC lead) 245

Action 2.1 - Consultation and collaboration on point-prevalence surveys: follow up discussion to 'Detect and Respond' session (CDC lead)

Action 3.7 - Alternatives to antimicrobials in veterinary medicine (USDA lead)

3:15-3:30 p.m. Break

246

247



3:30-5 p.m.	Session 2	
	Actions 1.5 and 1.7 – Surveillance and next generation sequencing (FDA lead)	245
	Action 2.5 - Coordinate guidance for detection of outbreaks or concerning resistance trends and appropriate response (ECDC lead)	246
	Action 3.3 - Research to improve the pipeline of antibacterial drugs for human medicine - Alignment of preclinical research/product development opportunities and clinical research programs. (NIH lead)	247
5:00-5:15 p.m.	Closing Larry Kerr, U.S. TATFAR Co-Chair	Aud. B1/B2
5:30-7 p.m.	Reception at CDC Museum Open to all attendees	CDC Museum

Friday, March 9

9 a.m1 p.m.	Closed Meeting for TATFAR Members	245/246
-------------	-----------------------------------	---------